To include your compound in the COVID-19 Resource Center, submit it here.

CTLA4-Ig: Phase IIb

In a double-blind, placebo-controlled Phase IIb trial in 339 RA patients, the percentage

Read the full 139 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE